However, for acquired regorafenib resistance developed in HCC patients, the combined use of TGF-β pathway inhibitors and Regorafenib constitute a promising approach for regorafenib sensitization and to prevent tumor recurrence. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.